Clinical trials. Diabetes' brave new world.
Couzin
Jennifer
J
D000293:Adolescent; D000328:Adult; D001323:Autoantibodies / Q000276:immunology; D002648:Child; D002986:Clinical Trials as Topic; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology / Q000517:prevention & control*; D018450:Disease Progression; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D007223:Infant; D007225:Infant Food; D007328:Insulin / Q000008:administration & dosage / Q000627:therapeutic use; D007515:Islets of Langerhans / Q000276:immunology; D016853:Muromonab-CD3 / Q000009:adverse effects / Q000627:therapeutic use; D009316:National Institutes of Health (U.S.); D009536:Niacinamide / Q000008:administration & dosage / Q000627:therapeutic use; D010455:Peptides / Q000627:therapeutic use; D012307:Risk Factors; D013601:T-Lymphocytes / Q000276:immunology; D018433:Twin Studies as Topic; D014481:United States
D001323:Autoantibodies; D007166:Immunosuppressive Agents; D007328:Insulin; D016853:Muromonab-CD3; D010455:Peptides; C112844:monoclonal antibody huOKT3(Ala-Ala); D009536:Niacinamide